Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

ck is a process designed to facilitate the development, and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.

During the first half of 2013 the Company will be having discussions with regulatory authorities regarding future clinical development plans for ibrutinib's use in patients with DLBCL. The Company expects to be able to provide further updates in the third quarter of 2013.

Conference Call and further Corporate UpdatesThe Company will hold a conference call today at 4:30 p.m. EST. To participate in the conference call, please dial 1-877-407-0778 for domestic callers and 1-201-689-8565 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at http://www.pharmacyclics.com.

Use of Non-GAAP Financial MeasuresThis press release contains non-GAAP financial measures, including operating expenses and other expenses adjusted to exclude certain non-cash expenses. These measures are not in accordance with, or an alternative to generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction w
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Quincy, MA (PRWEB) September 02, 2014 ... announced today the signage of a distribution agreement ... Azelis is now distributing Myriant’s bio-succinic acid in ... Kingdom and Ireland, targeting customers in the industrial ... chemical distribution powerhouse, Azelis offers a far-reaching chemical ...
(Date:9/2/2014)... - Oncothyreon Inc. (Nasdaq: ONTY ) announced today that ... will present at the Rodman & Renshaw 16 th ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... presentation will be accessible by visiting the Oncothyreon website ... About Oncothyreon Oncothyreon is a biotechnology ...
(Date:9/2/2014)... BETHESDA, Md. , Sept. 2, 2014  Spherix ... fostering and monetization of intellectual property, today announced that ... three patents to the Company in the month of ... of patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is expected ... million in 2014, growing at a CAGR of ... synthesis market is categorized on the basis of ... The synthesized oligonucleotides segment is expected to register ... market during the forecast period, owing to an ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... on Successful Use of New PGD Technique to be ... Society for Reproductive Medicine (ASRM) Annual Meeting -, ... Screening, for Spontaneous Pregnancies as well as PGD ... LIVINGSTON, N.J., Oct. 15 Empire,Genomics, developing high throughput ...
... (Amex:,ADL), developer and marketer of tests for the early ... it has filed with the U.S.,Food & Drug Administration ... ELISA tumor marker test for use as an aid ... guidance provided at the meeting they had with the ...
... innovate, relying on external technologies sourced from start-ups, ... players interact to bring science-driven innovation to market" ... speakers at the third annual Lux Executive Summit: ... October 15-16, 2007 at the Charles Hotel in ...
Cached Biology Technology:Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 3AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients 2Lux Executive Summit announces 2007 speakers 2
(Date:9/2/2014)... DURHAM, N.C. -- When you accidentally touch a hot ... know the basic neural circuits involved in sensing and ... out the molecular players. , Duke researchers have made ... molecule involved in pain in worms, and have built ... Sept. 2 in Nature Communications , may help ...
(Date:9/1/2014)... Dietary quality in the U.S. has improved steadily in ... intakebut overall dietary quality remains poor and disparities continue ... a new study from Harvard School of Public Health ... to date that the extensive efforts by many groups ... some payoff, but it also indicates that these efforts ...
(Date:9/1/2014)... Within minutes after birth, every child in the U.S. ... host of conditions, including sickle cell disease. Thousands of ... lucky, meaning many suffer and die from the disease ... a halt to at least some of those deaths. ... Biology working in the lab of George Whitesides, the ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... potential for breakthroughs in science and engineering research, twenty ... computing time at Argonne,s Leadership Computing Facility (ALCF) through ... Impact on Theory and Experiment (INCITE) program. The ... 66 scientific projects announced by DOE,s Office of Science ...
... help physicians screen pregnant women at risk of developing ... been developed at The University of Western Ontario and ... Institute. The technology, employing a panel of biomarkers ... women who develop preeclampsia, has been licensed to California-based ...
... B. Field, director of Carnegie,s Department of Global Ecology, ... of Embryology, have been elected AAAS Fellows by the ... appears in the News & Notes section of the ... two researchers are among 486 members who have been ...
Cached Biology News:Argonne advancing DOE INCITE scientific research projects 2Argonne advancing DOE INCITE scientific research projects 3New technology aims to reduce maternal and neonatal deaths 2
Request Info...
FITC~Bovine Serum Albumin...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Biology Products: